Bryan McMichael currently serves as the Interim Chief Financial Officer at Coherus BioSciences, Inc., a position he assumed in 2023. In this role, McMichael is responsible for overseeing the financial operations and strategy of the company, which focuses on the development and commercialization of biosimilar therapeutics. His leadership has been pivotal in navigating the company through a period of transition, ensuring financial stability and growth. Prior to joining Coherus BioSciences, McMichael built an impressive career in the finance sector, with extensive experience in both the pharmaceutical and biotech industries. He has held various senior financial positions at renowned companies, where he demonstrated a strong ability to drive financial performance and strategic initiatives. McMichael's expertise in financial planning, analysis, and corporate strategy has been recognized throughout his career, earning him a reputation as a skilled and visionary leader in the field. McMichael's appointment as Interim CFO at Coherus BioSciences came at a crucial time for the company, as it continues to expand its portfolio of biosimilar products and strengthen its position in the market. Under his guidance, the company has maintained a focus on sustainable growth and innovation, leveraging his deep understanding of the industry to navigate challenges and capitalize on opportunities. McMichael's leadership and financial acumen are instrumental in driving Coherus BioSciences towards its goal of improving patient access to high-quality, affordable biologics.